Clinical Trial Update: Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence [Phase 3]

View source ↗

Summary

Phase 3 trial update for CAM2038, a long-acting subcutaneous buprenorphine injection, in opioid use disorders has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid Use Disorder

Drugs mentioned

• CAM2038 (buprenorphine)

Snippet

Sponsor: Braeburn Pharmaceuticals | Conditions: Opioid Use Disorders | Phase 3 | Status: COMPLETED | Results posted: 2019-08-22